Analysts Set Eiger Biopharmaceuticals Inc. (EIGR) PT at $28.17

Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) has received an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $29.50.

A number of brokerages recently weighed in on EIGR. Oppenheimer set a $26.00 target price on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 12th. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Wedbush dropped their target price on shares of Eiger Biopharmaceuticals from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday. ValuEngine lowered shares of Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $17.00 target price (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th.

How to Become a New Pot Stock Millionaire

Shares of EIGR stock traded up $0.10 during trading hours on Wednesday, hitting $10.10. 65,330 shares of the company were exchanged, compared to its average volume of 62,597. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.58. Eiger Biopharmaceuticals has a 12-month low of $6.10 and a 12-month high of $16.20. The company has a market capitalization of $105.27, a price-to-earnings ratio of -2.07 and a beta of 1.70.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.02) by ($0.09). equities research analysts anticipate that Eiger Biopharmaceuticals will post -4.42 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in EIGR. Prosight Management LP purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at $9,469,000. Jennison Associates LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at $8,430,000. Armistice Capital LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at $5,357,000. Stonepine Capital Management LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at $2,093,000. Finally, Sphera Funds Management LTD. raised its stake in Eiger Biopharmaceuticals by 35.0% during the third quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after purchasing an additional 134,968 shares in the last quarter. 68.96% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Eiger Biopharmaceuticals Inc. (EIGR) PT at $28.17” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3297160/analysts-set-eiger-biopharmaceuticals-inc-eigr-pt-at-28-17.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q2 2018 EPS Estimates for TCF Financial Co.  Boosted by Analyst
Q2 2018 EPS Estimates for TCF Financial Co. Boosted by Analyst
Q2 2018 EPS Estimates for Wabtec Co. Decreased by B. Riley
Q2 2018 EPS Estimates for Wabtec Co. Decreased by B. Riley
Spirent  Insider Eric G. Hutchinson Purchases 206 Shares
Spirent Insider Eric G. Hutchinson Purchases 206 Shares
Q1 2018 EPS Estimates for Chesapeake Energy  Lowered by Imperial Capital
Q1 2018 EPS Estimates for Chesapeake Energy Lowered by Imperial Capital
ANI Pharmaceuticals  Stock Rating Lowered by BidaskClub
ANI Pharmaceuticals Stock Rating Lowered by BidaskClub
Achillion Pharmaceuticals  Upgraded to “Buy” by Zacks Investment Research
Achillion Pharmaceuticals Upgraded to “Buy” by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.